Comparison of methods to assess onset of breast development in the LEGACY Girls Study: methodological considerations for studies of breast cancer

Lauren C. Houghton1*, Julia A. Knight2,3, Mary Jane De Souza4, Mandy Goldberg1, Melissa L. White1, Karen O’Toole5, Wendy K. Chung6,7, Angela R. Bradbury5,10,11, Mary B. Daly12, Irene L. Andrulis2,13, Esther M. John14,15,16, Saundra S. Buys5 and Mary Beth Terry1,6

Abstract

Background: Younger age at onset of breast development, which has been declining in recent decades, is associated with increased breast cancer risk independent of age at menarche. Given the need to study the drivers of these trends, it is essential to validate methods to assess breast onset that can be used in large-scale studies when direct clinical assessment of breast onset is not feasible.

Methods: Breast development is usually measured by Tanner stages (TSs), assessed either by physical examination or by mother’s report using a picture-based Sexual Maturation Scale (SMS). As an alternative, a mother-reported Pubertal Development Scale (PDS) without pictures has been used in some studies. We compared agreement of SMS and PDS with each other (n = 1022) and the accuracy of PDS with clinical TS as a gold standard for the subset of girls with this measure (n = 282) using the LEGACY cohort. We further compared prediction of breast onset using ROC curves and tested whether adding urinary estrone 1-glucuronide (E1G) improved the AUC.

Results: The agreement of PDS with SMS was high (kappa = 0.80). The sensitivity of PDS vs clinical TS was 86.6%. The AUCs for PDS alone and SMS alone were 0.88 and 0.79, respectively. Including E1G concentrations improved the AUC for both methods (0.91 and 0.86 for PDS and SMS, respectively).

Conclusions: The PDS without pictures is a highly accurate, sensitive, and specific method for assessing breast onset, especially in settings where clinical TS is not feasible. In addition, it is comparable to SMS methods with pictures and thus easier to implement in large-scale studies, particularly phone-based interviews where pictures may not be available. Urinary E1G can improve accuracy over than PDS or SMS alone.

Keywords: Breast development, Breast cancer, Measurement, Puberty

Background

Puberty is an important stage of development that impacts future breast cancer risk [1]. Recent increases in the incidence of early-onset invasive breast cancer [2] may be related to recent declines in the age at initiation of breast development [3]. Earlier age at breast onset, independent of age at menarche, which unlike age at breast development has been more stable in recent decades, has been found to be associated with an increased risk for breast cancer [4]. Large-scale epidemiologic studies investigating factors that may explain risk of early breast onset are needed across diverse populations. Therefore, it is important to use methods that can assess the timing of breast onset that are both sensitive and specific as well as feasible in large-population studies. Because timing of breast onset has been shown to vary by ethnicity and obesity [5–7], it is also important to...
evaluate whether different methods to assess the onset of breast development vary by these factors.

Breast development can be measured by physical examination by clinicians or through guardian report or self-report based on questionnaires, either with or without picture prompts. Clinicians perform a visual and physical assessment, sometimes with palpation, of breast development according to Tanner stages (TSs) established in 1969 [8]. Although clinician assessment via physical examination is considered the gold standard [9, 10], self-reports and guardian reports are often used in lieu of the physical examination, especially in large-scale epidemiological studies in which conducting physical examinations is often not feasible. One such method is the Sexual Maturation Scale (SMS), a questionnaire-based tool that asks respondents to rate breast development based on pictures that correspond with the five TSs [11]. Another commonly used questionnaire-based instrument is the Pubertal Development Scale (PDS) [12]. A key advantage of the PDS is that it is question-based and does not involve pictures and can therefore be queried over the phone and/or more easily included in questionnaires.

Given the need to have scalable methods that accurately reflect pubertal development stage, the purpose of the present study was to compare the SMS and PDS with clinical TS to assess the specificity and sensitivity of reported measures of breast onset. Given that estrogens lead to increased epithelial proliferation in terminal end buds of the mammary gland, resulting in the onset of breast development [13], a secondary aim of this study was to evaluate whether the assessment of hormonal measures in premenarcheal girls increases the validity of guardian-reported methods of breast onset. Estrone 1-glucuronide (E1G), an estrogen metabolite in urine, is an indicator of total circulating estrogens, which rise before puberty [14]. Previous studies have found both the PDS and SMS to be accurate measures of breast development [15–18], but none have simultaneously compared SMS, PDS, and hormonal biomarkers with clinical TS.

**Methods**

**Study population**

The LEGACY Girls Study is a five-site study of pubertal development in 1040 girls ages 6–13 years at recruitment, half of whom have a family history of breast cancer (for details, see [19, 20]). Prior validation studies have not been conducted in cohorts enriched with individuals who have a family history of breast cancer. Because pubertal development measures are important to breast cancer risk, it is essential to evaluate whether differential measurement error exists based on breast cancer family history. Across all five study sites, classification of pubertal timing was based on the Growth and Development Questionnaire, which includes both the PDS [12] and SMS [11]. Mothers/guardians for girls of all ages and girls aged 10 years or older completed the questionnaire every 6 months. Because 97% of girls participated with their biological mother [19], we refer to them as the mother for the remainder of the paper. For the purpose of this study, we used the first available mother reports of breast onset.

**Tanner staging**

TS assessment includes evaluation of the development of both breasts and areolae, with TS1 representing pre-pubertal development, TS2 representing the onset of breast development, TS3 representing further enlargement of breast and areola without separation of their contour, TS4 representing the areola and papilla forming a secondary mound above the level of the breast, and TS5 representing full breast maturity.

**Pubertal Development Scale**

Using the PDS, mothers assessed breast development by responding to the question, “How far along is your daughter in the development of her breasts?” with five possible answer options: (1) has not yet started breast development, (2) barely started breast development, (3) breast development is definitely underway, (4) breast development seems complete, or (5) no answer. Option 2, “barely started,” corresponds with the onset of breast development and TS2 [12].

**Sexual Maturation Scale**

The SMS instructions were as follows: “The drawings below show five different stages of breast development. A girl can go through each of the five stages, although some girls skip some stages. Look at each drawing, and read the description. Which of these drawings looks most like your daughter’s stage of development?” Mothers rated their daughter’s breast development by selecting one of five line drawings showing TS1–TS5 [11]. We collapsed stages 4 and 5 to convert the SMS 5-point scale into a 4-point scale to directly compare with the PDS. TS2 marks the onset of breast development.

**Clinical TS**

At two study sites, trained research staff or a physician performed standardized clinical breast Tanner staging on 282 girls [21]. Three clinical raters from New York and one from Utah were trained concurrently on the determination of breast TS using visual inspection along with palpation when necessary. If it was difficult to distinguish between breast bud development (TS2) and fat tissue, then the breast was palpated with the girl’s permission, and a second score based on both visualization and palpation was recorded. As in the SMS, breast onset is marked by TS2. Clinician interrater
reliability for Tanner breast stage was high, with weighted kappa scores ranging from 0.93 to 1.00 and kappa scores for T2+ vs T1 of 0.94–1.00 [21].

**Hormone measurement**

Microtiter plate competitive enzyme immunoassays (EIAs) were used to measure E1G, which was assessed in a first-morning void provided by premenarcheal girls at the same clinical visit as when maternal PDS and SMS and clinical TS were reported. The E1G EIA uses a polyclonal capture antibody R522-2 from Coralie Munroe at the University of California (Davis, CA, USA). The competitor for this assay is E1G conjugated to horseradish peroxidase [22]. An endpoint substrate color reaction is developed with azino-bis-ethylbenzthiazoline sulfonic acid and peroxidase. E1G standards from Sigma-Aldrich (St. Louis, MO, USA) were used for the standard curves, and high and low internal controls were in-house samples. The interassay coefficients of variation for high and low internal controls for the E1G assay were 14.7% and 13.1%, respectively. The sensitivity of the E1G assay was 5.2 ng/ml. All urine samples were corrected for specific gravity using a hand refractometer (NSG Precision Cells, Inc., Farmingdale, NY, USA), and the concentration determined from the assay was divided by the specific gravity to correct for hydration status [23–26].

**Additional covariates**

At each study visit, height and weight were measured twice by trained research staff. Averaging the two measures, we calculated age-specific height, weight, and body mass index (BMI) percentiles based on Centers for Disease Control and Prevention (CDC) growth charts [27]. Girls were classified as overweight if their BMI was equal to or above the 85th percentile. Girls were classified as having a family history of breast cancer if the participating mother reported a breast cancer family history in the daughter’s first- or second-degree relatives.

**Statistical models**

We calculated percent agreement and kappa statistics between the first available mother’s report of breast onset using the question-only PDS and the picture-based SMS. We also assessed the sensitivity and specificity of PDS using the clinical TS as the gold standard. To examine whether mother’s reports for some subgroups of girls were less accurate, we assessed whether age, breast cancer family history, BMI, or race/ethnicity influenced the accuracy of the mother’s classification. We generated ROC curves to compare the PDS and SMS with clinical TS. We compared assessment of breast onset in two ways: we compared T2 with T1 and T2—T5 (T2+) with T1. We tested if adding other covariates improved the AUC of these models. Using Weibull models, we compared the median age at breast onset derived from the two mother’s report methods (PDS and SMS) with the median age from the clinical TS in a subset of girls who had all three measures at baseline (n = 200). We also compared the different pubertal staging methods with first morning urinary E1G concentrations that were collected at the same clinical visit as the PDS, SMS, and clinical TS. We used linear regression to compare E1G, after logarithmic transformation, at each stage of breast development as reported by mothers using the PDS and SMS. Data are reported as the mean and 95% CI with SEM.

**Results**

**PDS vs SMS**

In the overall cohort (N = 1022 with complete information; see Additional file 1: Table S1), PDS and SMS reports of breast onset stage were in high agreement (89.6%) (Table 1). The overall weighted kappa value was 0.80. The weighted kappa value was higher for reports from mothers of girls younger than 10 years old than from mothers of girls aged 10 years or older (Table 1).

**PDS vs clinical TS**

PDS was also highly accurate in relation to clinical TS (87.9%) (Table 2). The overall weighted kappa value was 0.80, and sensitivity and specificity were 86.6% and 89.6%, respectively. Sensitivity was lower for reports from mothers of younger daughters than older daughters (62.5% vs 91.8%), but specificity was higher (95.8% vs 45%). Sensitivity was similar between mothers of girls with positive and negative family histories. Mothers of overweight girls (as defined on the CDC 85th percentile) had higher sensitivity (96.9% vs 83.0%) but lower specificity than mothers of nonoverweight girls (65.0% vs 93.1%).

**Hormone concentration by pubertal staging**

Mean concentrations of E1G increased incrementally with each maturity stage as measured by PDS, SMS, or clinical TS (Table 3). Hormones were statistically higher in each subsequent stage for each assessment method. E1G concentrations were 0.80–0.88 ng/ml higher in girls rated at T2+ than girls in T1 across all measures. Girls with breast onset (T2+) according to any of the three different methods had E1G levels above 2 ng/ml, suggesting a possible hormonal threshold for breast onset.

The distribution of E1G in the subset of girls (n = 153) with all three (PDS, SMS, and clinical TS) measures of breast development and a hormone measurement available is shown in Fig. 1. Mean E1G values were 1.2 ng/ml in girls at stage 1 and 2.3 ng/ml in girls at T2+ when all three methods of breast onset were concordant. Values
ranged from 1.5 to 1.8 ng/ml for girls with at least one discordant measure.

Using clinical TS as the gold standard, the AUC (TS1 vs TS2+) for PDS alone was higher (0.88) than for SMS (0.78) alone (Table 4) or E1G alone (0.77). The AUCs for both PDS and SMS improved with the inclusion of hormone measurements (AUC = 0.91 and 0.86 for PDS and SMS, respectively). Adding additional predictors such as race/ethnicity, overweight status, and family history improved the AUC by 1% or less.

Impact on predicted median age at breast onset
The median ages (IQR) at breast onset were 9.9 years (9.1 – 10.5), 10.8 (9.7 – 11.8), and 10.1 (9.0 – 11.1) as assessed by the PDS, SMS, and clinical TS, respectively (Fig. 2). This translates to PDS underestimating age at breast onset by 2.4 months and SMS overestimating it by 8.4 months.

Discussion
Our results demonstrate that breast onset determined by mother’s report using the PDS corresponds well with both clinical TS (the existing gold standard) and the physiological changes in gonadal steroid hormone concentrations that drive pubertal maturation. Furthermore, the discrimination from mother’s report of breast onset using the PDS in predicting TS2+ was better than using mother’s report of SMS. Our findings also suggest that E1G in combination with mother’s report further improves the discrimination of breast onset. Although the majority of puberty studies use clinical TS to assess breast onset [28–33], large-scale studies of pubertal development using mother’s report without a clinical visit can produce accurate and valid measures of breast onset, particularly when additional hormone measures are added.

Mother’s report using PDS had higher discrimination, agreement, and accuracy than mother’s report using SMS. We previously published the kappa values and percent agreement between mother’s report using SMS with clinical TS in the same cohort and found agreement with clinical TS to be 73% compared with the 88% reported here with PDS [21]. Mothers were less accurate at identifying TS2+ when using SMS, perhaps because the pictures of TS2 capture size in addition to areolar development, leading mothers to downgrade their

### Table 1 Agreement between Pubertal Development Scale and Sexual Maturation Scale methods of assessing breast onset, by sample characteristics in the LEGACY Girls Study

| Description                  | PDS a vs SMS b | 2+ vs 1 | Agreement | Kappa value | 95% CI  |
|------------------------------|----------------|---------|-----------|-------------|---------|
| No. of subjects              |                |         |           |             |         |
| All ages combined            | 1022           | 89.6    | 0.8       | 0.7–0.9     |         |
| Daughter aged < 10 years     | 500            | 92.4    | 0.7       | 0.6–0.8     |         |
| Daughter aged ≥ 10 years     | 522            | 87      | 0.5       | 0.4–0.6     |         |
| Family history               |                |         |           |             |         |
| Positive                     | 529            | 90.9    | 0.8       | 0.7–0.9     |         |
| Negative                     | 493            | 88.2    | 0.8       | 0.7–0.9     |         |
| BMI percentile c             |                |         |           |             |         |
| BMI ≥ 85th percentile        | 188            | 90.4    | 0.8       | 0.7–0.9     |         |
| BMI < 85th percentile        | 815            | 89.6    | 0.8       | 0.7–0.9     |         |
| Race/ethnicity               |                |         |           |             |         |
| White non-Hispanic           | 636            | 89.8    | 0.8       | 0.7–0.9     |         |
| Hispanic                     | 189            | 89.9    | 0.8       | 0.7–0.9     |         |
| Other (black, Asian, other)  | 197            | 88.8    | 0.7       | 0.7–0.9     |         |
| Site                         |                |         |           |             |         |
| Philadelphia                 | 152            | 92.3    | 0.7       | 0.6–0.8     |         |
| New York                     | 166            | 92.2    | 0.7       | 0.6–0.8     |         |
| Utah                         | 161            | 92.8    | 0.7       | 0.6–0.8     |         |
| Ontario                      | 191            | 93.3    | 0.8       | 0.7–0.9     |         |
| California                   | 352            | 91.2    | 0.7       | 0.6–0.8     |         |

**Abbreviations:** BMI Body mass index, PDS Pubertal Development Scale, SMS Sexual Maturation Scale

aPDS is a questionnaire-based assessment of breast development without pictures

bSMS is a questionnaire-based assessment of breast development that uses pictures to illustrate the five Tanner stages of breast development

*Missing BMI for 19 girls
daughter’s breast development. However, the PDS questions preceded the SMS pictures, and this order of administration may have affected the comparison as well. The kappa value and percent accuracy of mother’s reports of breast onset using either the PDS or SMS compared with clinical TS were consistent and higher in our study than those previously reported in other studies of pubertal development [15–17]. Specifically, in a study consisting of 78 girls (aged 9–14 years), the kappa value between mother’s report using either PDS or SMS compared with clinical TS was 0.36 with 47–49% agreement [15]. The age range of girls in our study was wider (6–16 years) than in other studies, allowing us to assess differences in accuracy according to age. We observed that mothers of young daughters (<10 years old) were accurate in reporting the absence of breast onset (specificity) and mothers of older daughters (≥10 years old) were accurate in reporting the presence of breast onset (sensitivity); thus, the wider age range and more mothers of young (6–9 years old) and older (14–16 years old) daughters in our cohort may explain the higher overall agreement in our study. Although we were unable to compare PDS and SMS with clinical TS in our full cohort, the sample size of the subset with all available

### Table 2 Accuracy of Pubertal Development Scale method of assessing breast onset compared with clinical Tanner scale, by sample characteristics in the LEGACY Girls Study

| Description                  | PDS \(^a\) vs clinical TS \(^b\) |
|------------------------------|---------------------------------|
|                              | 2+ vs 1                         |
|                              | No. of subjects | Accuracy (%) | Kappa value | 95% CI | Sensitivity | Specificity |
| All ages combined            | 282              | 87.9          | 0.8         | 0.7–0.9 | 86.6        | 89.6        |
| Daughter aged < 10 years     | 165              | 91.9          | 0.6         | 0.4–0.8 | 62.5        | 95.8        |
| Daughter aged ≥ 10 years     | 117              | 83.8          | 0.4         | 0.2–0.6 | 91.8        | 45          |
| Family history               |                  |               |             |        |             |             |
| Positive                     | 122              | 89.3          | 0.8         | 0.6–1.0 | 86.6        | 92.2        |
| Negative                     | 155              | 87.5          | 0.7         | 0.5–0.9 | 86.7        | 88          |
| BMI percentile\(^c\)         |                  |               |             |        |             |             |
| BMI ≥ 85th percentile        | 50               | 84.6          | 0.7         | 0.4–0.9 | 96.9        | 65          |
| BMI < 85th percentile        | 223              | 89.1          | 0.8         | 0.7–0.9 | 83          | 93.1        |
| Race/ethnicity               |                  |               |             |        |             |             |
| White non-Hispanic           | 189              | 87.9          | 0.7         | 0.6–0.8 | 100         | 100         |
| Hispanic                     | 60               | 90            | 0.8         | 0.5–1.1 | 84.8        | 89.9        |
| Other (black, Asian, other)  | 33               | 87.9          | 0.8         | 0.5–1.1 | 81.3        | 94.1        |
| Site                         |                  |               |             |        |             |             |
| New York                     | 135              | 89.6          | 0.8         | 0.6–1.0 | 86.7        | 92          |
| Utah                         | 147              | 86.4          | 0.7         | 0.5–0.9 | 84.5        | 87.6        |

**Abbreviations:** BMI Body mass index, PDS Pubertal Development Scale, TS Tanner scale

\(^a\)PDS is a questionnaire-based assessment of breast development without pictures

\(^b\)Clinical TS is a physical examination of breast development and rated according to the five Tanner stages of breast development

\(^c\)Missing BMI for 19 girls

### Table 3 Mean urinary estrone 1-glucuronide levels and 95% CIs across stages of puberty, according to Pubertal Development Scale and Sexual Maturation Scale in the LEGACY Girls Study

| Stage | PDS \(^a\) | SMS \(^b\) | Clinical TS \(^c\) |
|-------|------------|------------|--------------------|
|       | No. of subjects | Mean (ng/ml) | 95% CI           | No. of subjects | Mean (ng/ml) | 95% CI           | No. of subjects | Mean (ng/ml) | 95% CI           |
| 1     | 96         | 1.25       | 1.11–1.39         | 116           | 1.34       | 1.21–1.47         | 103           | 1.29       | 1.16–1.43         |
| 2     | 36         | 1.91       | 1.51–2.32         | 20            | 2.07       | 1.61–2.54         | 36            | 1.96       | 1.56–2.36         |
| 3     | 21         | 2.34       | 1.87–2.81         | 13            | 2.30       | 1.76–2.83         | 11            | 2.31       | 1.74–2.89         |
| 4     | 0          | 2.76       | 1.92–3.59         | 3             | 3.04       | 1.98–3.87         |               |            |                  |
| 2–4   | 57         | 2.07       | 1.70–2.44         | 37            | 2.23       | 1.83–2.62         | 50            | 2.10       | 1.72–2.47         |

**Abbreviations:** PDS Pubertal Development Scale, SMS Sexual Maturation Scale, TS Tanner scale

\(^a\)PDS is a questionnaire-based assessment of breast development without pictures

\(^b\)SMS is a questionnaire-based assessment of breast development that uses pictures to illustrate the five Tanner Stages of breast development

\(^c\)Clinical TS is a physical examination of breast development and rated according to the five Tanner stages of breast development
measures was larger than that in any previous studies which have assessed mother’s reports of breast development [15–18]. Our present results and other recent results [15] differ from those of a 2002 review of pubertal assessment methods in which the authors concluded that the PDS was the least valid method compared with SMS and other methods. The studies that have shown the utility of PDS [15, 16] were not included in the review, and none of the studies reviewed included hormone measures [7].

We found that including a urinary estrogen metabolite in addition to mother’s report further improved the discrimination of breast onset (TS2+). Investigators planning to assess breast onset may want to consider incorporating estrogen biomarkers in their pubertal assessment because including E1G in our study improved the AUC by up to 0.11. However, estrogen alone does not fully capture clinically assessed breast onset, because there is substantial overlap in hormone-level distributions between stages of breast development, as we and others have shown [15, 34, 35]. Prior studies proposed that relatively weak correlations between clinician’s and mother’s reports of breast development and hormone levels may be due to accounting inadequately for menstrual cycle phase of biospecimen collection [15, 34]. However, menstrual cycle day is not a source of variation in our study, because all estrogen measures were taken from premenarcheal girls. Rather, some of the wide variation in E1G in TS2 across all assessment methods may be explained by the inclusion of girls with transient thelarche as well as girls with permanent thelarche in this group (see Fig. 1). Girls with transient thelarche (i.e., the appearance of breast onset that regresses and appears again) have lower hormone profiles than girls with permanent thelarche [36]. Whether to include estrogen measurement in a study design of pubertal development depends on the overall intent of the study. For example, for studies where there is interest in identifying breast onset as a period of breast cancer susceptibility, transient thelarche may be sufficiently captured by PDS assessment method (and estrogen measurement is not necessary), because the appearance of breast tissue marks a period of cell proliferation and rapid breast tissue development.

Because we have shown that estimates of age at breast onset, typically the first sign of pubertal development, differ depending on the assessment method, the degree of misclassification by each method has implications when...
using pubertal onset as either an outcome or a parameter to define the pubertal window of susceptibility. A focus of pediatric research since the 1990s has been determining whether there is a secular decline in the age at breast onset [9]. Although it appears that there has been a decline in the age at breast onset [5, 6, 37], one of the main critiques of early studies of pubertal timing in the United States was that even the gold standard, clinical breast Tanner staging, was limited if palpation was not performed [38]. There was concern that physical examination without palpation could not accurately distinguish true TS2 from lipomastia caused by obesity. In our study, two of the LEGACY sites used clinically trained providers to measure TS with palpation when necessary to rule out misclassification due to lipomastia. Measuring clinical TS may also still be extremely useful in young girls because the specificity of PDS is still very low in mothers of young girls. Until the assessment of breast onset is standardized, one way to draw comparisons across future studies is to assess breast onset using all three methods in a subset of the study population, particularly in young girls, so that final estimates can be adjusted for measurement error [20]. For studies that cannot implement all three methods, the measurement error estimates from our study can be used, as long as the limitations of our study are considered.

**Table 4** Discrimination of the Pubertal Development Scale and Sexual Maturation Scale compared with clinical Tanner stage, as assessed by AUC in the LEGACY Girls Study

|                      | Clinical Tanner stage (T1 vs T2+) AUC (n = 153) | Clinical Tanner stage (T1 vs T2) AUC (n = 153) |
|----------------------|-----------------------------------------------|-----------------------------------------------|
| **Model A**          |                                               |                                               |
| PDS[^a]              | 0.88                                          | 0.84                                          |
| E1G (ng/ml)          | 0.91                                          | 0.87                                          |
| Race/ethnicity       | 0.89                                          | 0.86                                          |
| Height (% for age)   | 0.89                                          | 0.84                                          |
| Weight (% for age)   | 0.88                                          | 0.84                                          |
| Overweight (> 85th percentile BMI) | 0.90   | 0.86                                          |
| Family history       | 0.87                                          | 0.83                                          |
| SMS[^b]              | 0.78                                          | 0.68                                          |
| E1G (ng/ml)          | 0.86                                          | 0.79                                          |
| Race/ethnicity       | 0.81                                          | 0.70                                          |
| Height (% for age)   | 0.78                                          | 0.68                                          |
| Weight (% for age)   | 0.78                                          | 0.68                                          |
| Overweight (> 85th percentile BMI) | 0.80   | 0.69                                          |
| Family history       | 0.78                                          | 0.68                                          |
| **Model B**          |                                               |                                               |
| PDS[^a]              | 0.88                                          | 0.84                                          |
| + E1G (ng/ml)        | 0.91                                          | 0.87                                          |
| + Race/ethnicity     | 0.91                                          | 0.88                                          |
| + Overweight (> 85th percentile BMI) | 0.92   | 0.88                                          |
| + Family history     | 0.92                                          | 0.88                                          |
| SMS[^b]              | 0.78                                          | 0.68                                          |
| + E1G (ng/ml)        | 0.86                                          | 0.79                                          |
| + Race/ethnicity     | 0.86                                          | 0.80                                          |
| + Overweight (> 85th percentile BMI) | 0.87   | 0.80                                          |
| + Family history     | 0.87                                          | 0.80                                          |
| **Model C**          |                                               |                                               |
| PDS, SMS, E1G        | 0.91                                          | 0.87                                          |

**Abbreviations:** BMI Body mass index, E1G Estrone 1-glucuronide, PDS Pubertal Development Scale, SMS Sexual Maturation Scale

Model A: These models compare mother’s report (PDS or SMS) with clinical TS and add each covariate one at a time

Model B: These models compare mother’s report (PDS or SMS) with clinical TS and are nested so that each subsequent covariate is added to the previous model

Model C: This model includes PDS, SMS, and E1G to test if the combination of all three measures yields a higher AUC than either PDS + E1G or SMS + E1G

[^a]PDS is a questionnaire-based assessment of breast development without pictures

[^b]SMS is a questionnaire-based assessment of breast development that uses pictures to illustrate the five Tanner Stages of breast development
breast cancer family history, our enriched study based on half of the participants having a breast cancer family history may not be generalizable to other populations. Our study also does not address whether mother’s report of breast onset would be a reliable measure in other countries; however, mothers living in selected cultures may prefer the PDS because it does use pictures of breasts.

Ultimately, assessing breast onset accurately in easily scalable ways is essential to advancing the understanding of how early life influences breast cancer risk, as well as understanding pubertal trends and their health impacts more broadly. Early breast onset (< 10 years old compared with 11–12 years) is associated with a 23% increased risk of breast cancer [4]. We found a 2- to 8-month difference in the age at onset, depending on whether mother’s report of breast onset was assessed by PDS or SMS. Considering that a 1-month delay in age at breast onset is related to a 1.6% decrease in breast cancer risk [4], it is important to consider the expected effect size of the association in relation to the size of measurement error. For example, in a recent longitudinal study of breast onset assessed by annual clinical TS, obesity (BMI > 95th percentile) was associated with an 8.4-month acceleration in median age of breast onset compared with nonobese U.S. girls (50th to < 85th percentile) [5]. The median age of breast onset was also 6.7 months earlier in this population of girls born between 1996 and 2002 compared with girls born between 1980 and 1990 [5, 6]. Both of these studies assessed breast onset using an annual clinical assessment of breast onset for the majority of their participants. However, in the study by Biro et al., only a subset of girls was assessed semiannually, and the authors explained that semiannual vs annual assessment could account for a 3- to 4-month difference in the age of breast onset between the studies [5]. A clear advantage of using PDS over clinical TS to assess breast onset are that (1) it can be implemented more frequently and in a more cost-effective and scalable manner, and (2) it may yield tighter estimates of median age of breast onset, especially for exposures of interest that may have associations of smaller magnitude than body size or secular time.

**Conclusions**

Mother’s report of breast onset using PDS is a viable alternative to mother’s report using SMS for large-scale epidemiological studies of breast onset. The method used for breast onset assessment alters the estimates of median age at onset, which has implications for studies of pubertal onset and studies of breast cancer concerned with pubertal timing. Including biomarkers related to breast onset, such as urinary estrogen, can improve the accuracy of pubertal assessments.

**Additional file**

**Additional file 1**: Table S1. Study characteristics in the cohort and subsets. (DOCX 14 kb)

**Abbreviations**

BMI: Body mass index; CDC: Centers for Disease Control and Prevention; E1G: Estrone 1-glucuronide; EIA: Enzyme immunoassay; PDS: Pubertal Development Scale; SMS: Sexual Maturation Scale; TS: Tanner stage

**Acknowledgements**

The authors thank the LEGACY girls and their family members for their continuing contributions to the study, as well as LEGACY study staff and our colleagues at the participating family genetics and oncology clinics.
Funding
This work was supported by the National Cancer Institute of the National Institutes of Health (grants CA138638 [to EMJ], CA138819 [to MBD], CA138822 [to MBT], and CA138844 [to ILA]) and the Canadian Breast Cancer Foundation (to ILA). ILA holds the Anne and Max Tanenbaum Chair in Molecular Medicine at the Sinai Health System and the University of Toronto.

Availability of data and materials
The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors’ contributions
LCH conceptualized the set of analyses presented in this article, conducted the data analysis and interpretation, and drafted the initial manuscript. MBT and JAK advised during the data analysis and interpretation and the drafting of the manuscript. MBT, EMJ, ILA, SSB, MBD, and ARB conceptualized the design of the overall parent study. MBT, EMJ, ILA, JAK, SSB, ARB, and WNC participated in the collection and assembly of data, analysis and interpretation, and manuscript writing for this paper. MG participated in the analysis and interpretation of the data and reviewed and revised the manuscript. MJDs oversaw the measurement of the hormone data and reviewed and revised the manuscript. MW and KOT conducted the clinical Tanner assessments. All authors read and approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Ethics approval and consent to participate
The Columbia University Medical Center Human Research Protection Office and institutional review boards (IRBs), the California Committee for the Protection of Human Subjects, the Mount Sinai Hospital Research Ethics Board, the University of Utah IRB, the Fox Chase Cancer Center IRB, the Children’s Hospital of Philadelphia IRB, and the University of Pennsylvania IRB approved the study. The girls’ mothers/ guardians provided written informed consent, and the girls provided assent based on institutional standards.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Epidemiology, Columbia University Mailman School of Public Health, 722 West 168th Street, New York, NY 10032, USA. 2Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada. 3Division of Epidemiology, Dalhousie School of Public Health, University of Toronto, Toronto, ON, Canada. 4Institute of Population Health, Queen’s University at Kingston, Kingston, ON, Canada. 5Department of Medicine, Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT, USA. 6Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA. 7Department of Pediatrics, Columbia University Medical Center, New York, NY, USA. 8Department of Medicine, Columbia University Medical Center, New York, NY, USA. 9Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 10Department of Medicine, Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 11Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 12Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA, USA. 13Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada. 14Cancer Prevention Institute of California, Fremont, CA, USA. 15Division of Epidemiology, Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA, USA. 16Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.

Received: 3 August 2017 Accepted: 16 February 2018
Published online: 18 April 2018

References
1. Forman MR, Winn OM, Collman GW, Rizzo J, Birnbaum LS. Environmental exposures, breast development and cancer risk through the looking glass of breast cancer prevention. Reprod Toxicol. 2015;54:6–10.
2. Johnson RH, Chien FL, Bleyer A. Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA. 2013;309(8):800–5.
3. Sørensen K, Mountsen A, Akoegbae L, Hagen CP, Mogensen SS, Juul A. Recent secular trends in pubertal timing: implications for evaluation and diagnosis of precocious puberty. Horm Res Paediatr. 2012;77:13–45.
4. Bodicoat DH, Schoemaker MJ, Jones ME, McFadden E, Griffin J, Ashworth A, et al. Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study. Breast Cancer Res. 2014;16:R18.
5. Biro FM, Greenspan LC, Galvez MP, Pinney SM, Teitelbaum S, Windham GC, et al. Onset of breast development in a longitudinal cohort. Pediatrics. 2013;132:1019–27.
6. Herman-Giddens ME, Sora EJ, Wasserman RC, Boudony CJ, Bhapkar MV, Koch GG, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics. 1997;99:505–12.
7. Houghton LC, Cooper GD, Bentley GR, Booth M, Chowdhury OA, Trosi R, Ziegler RG, Hoover RN, Kati HA. A migrant study of pubertal timing and tempo in British-Bangladeshi girls at varying risk for breast cancer. Breast Cancer Res. 2014;16(6):469. https://doi.org/10.1186/s13058-014-0469-8.
8. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44:291–303.
9. Euling SY, Herman-Giddens ME, Lee PA, Selevan SG, Juul A, Sørensen TI, et al. Examination of US puberty-timing data from 1940 to 1994 for secular trends: panel findings. Pediatrics. 2008;121(Suppl):S172–91.
10. Coleman L, Coleman J. The measurement of puberty: a review. J Adolesc. 2002;25:535–50.
11. Morris NM, Udy JR. Validation of a self-administered instrument to assess stage of adolescent development. J Youth Adolesc. 1980;29:271–80.
12. Petersen AC, Crockrell L, Richards M, Boxer A. A self-report measure of pubertal status: reliability, validity, and initial norms. J Youth Adolesc. 1988;17:17–33.
13. Bennyhill GE, Trott JV, Hovey RC. Mammary gland development—it’s not just about estrogen. J Dairy Sci. 2016;99:875–83.
14. Biro FM, Pinney SM, Huang B, Baker ER, Chandler DW, Dorn LD. Hormone changes in peripubertal girls. J Clin Endocrinol Metab. 2014;99:3829–35.
15. Shirtcliff EA, Dahl RE, Pollak SD. Pubertal development: correspondence between hormonal and physical development. Child Dev. 2009;80:327–37.
16. Brooks-Gunn J, Warren MP, Rosso J, Gargiulo J. Validity of self-report measures of girls’ pubertal status. Child Dev. 1987;58:829–41.
17. Dorn LD, Susman EJ, Nettleton MD, Inoff-Germain C, Chousos GP. Perceptions of puberty: adolescent, parent, and health care personnel. Dev Psychol. 1990;26:322–9.
18. DeWalt DA, Gross HE, Gipson DS, Slevicki DT, DeWitt EM, Dampier CD, et al. PROMIS® pediatric self-report scales distinguish subgroups of children within and across six common pediatric chronic health conditions. Qual Life Res. 2015;24:2195–208.
19. John EM, Terry MB, Keegan THM, Bradbury AR, Knight JA, Chung WK, et al. The LEGACY Girls Study. Epidemiology. 2016;27:438–48.
20. Terry MB, Keegan THM, Houghton LC, Goldberg M, Andrulis IL, Daly MB, et al. Pubertal development in girls by breast cancer family history: the LEGACY girls cohort. Breast Cancer Res. 2017;19:69.
21. Terry MB, Goldberg M, Schechter S, Houghton LC, White ML, O’Toole K, et al. Comparison of clinical, maternal, and self pubertal assessments: implications for health studies. Pediatrics. 2016;138(5):e20154571.
22. Munro CJ, Stabenfeldt GD, Craupan JR, Addiego LA, Overstreet JW, Lasley BL. Relationship of serum estradiol and progesterone concentrations to the excretion profiles of their major urinary metabolites as measured by enzyme immunoassay and radioimmunoassay. Clin Chem. 1991;37:838–44.
23. Haddow JE, Knight GJ, Palomaki GE, Neveux LM, Chilmonczyk B. Replacing creatinine measurements with specific gravity values to adjust urine cotinine concentrations. Clin Chem. 1994;40:562–4.
24. Goldberger BA, Loewenthal B, Darwin WD, Cone EJ. Intrasubject variation of creatinine and specific gravity measurements in consecutive urine specimens of heroin users. Clin Chem. 1995;41:116–7.
25. Bell DR, Clode S, Fan MQ, Fernandes A, Foster PMD, Jiang T, et al. Toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the developing male Wistar(Han) rat. III. Chronic dosing causes developmental delay. Toxicol Sci. 2007;99:224–33.
26. Miller RC, Brindle E, Holman DJ, Shofer J, Klein NA, Soules MR, et al. Comparison of specific gravity and creatinine for normalizing urinary reproductive hormone concentrations. Clin Chem. 2004;50:924–32.
27. Kuczynski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, et al. CDC growth charts for the United States: methods and development. Vital Health Stat 11. 2002;246:1–190.
28. Biro FM, Galvez MP, Greenspan LC, Succop PA, Vangeepuram N, Pinney SM, et al. Pubertal assessment method and baseline characteristics in a mixed longitudinal study of girls. Pediatrics. 2010;126:e583–90.
29. Richter L, Norris S, Pettifor J, Yach D, Cameron N. Cohort profile: Mandela’s children: the 1990 Birth to Twenty study in South Africa. Int J Epidemiol. 2007;36:504–11.
30. Ruder EH, Hartman TJ, Dorgan JF. Birth characteristics and age at menarche: results from the Dietary Intervention Study in Children (DISC). Cancer Causes Control. 2010;21:1379–86.
31. Pinkney J, Streeter A, Hosking J, Mostazir M, Mohammad M, Jeffery A, et al. Adiposity, chronic inflammation, and the prepubertal decline of sex hormone binding globulin in children: evidence for associations with the timing of puberty (Earlybird SB). J Clin Endocrinol Metab. 2014;99:3224–32.
32. Lee HA, Kim YJ, Lee H, Gwak HS, Hong YS, Kim HS, et al. The preventive effect of breast-feeding for longer than 6 months on early pubertal development among children aged 7–9 years in Korea. Public Health Nutr. 2015;18:3300–7.
33. Berkey CS, Willett WC, Frazer AL, Rosner B, Tamimi RM, Colditz GA. Prospective study of growth and development in older girls and risk of benign breast disease in young women. Cancer. 2011;117:1612–20.
34. Huang B, Hillman J, Biro FM, Ding L, Dorn LD, Susman EJ. Correspondence between gonadal steroid hormone concentrations and secondary sexual characteristics assessed by clinicians, adolescents, and parents. J Res Adolesc. 2012;22:381–91.
35. Nottelmann ED, Susman EJ, Dorn LD, Inoff-Germain G, Loriaux DL, Cutler GB, et al. Developmental processes in early adolescence: Relations among chronologic age, pubertal stage, height, weight, and serum levels of gonadotropins, sex steroids, and adrenal androgens. J Adolesc Health Care. 1987;8:246–60.
36. Lindhardt Johansen M, Hagen CP, Mientz MG, Wolthers OD, Heuck C, Petersen JH, et al. Pubertal progression and reproductive hormones in healthy girls with transient thelarche. J Clin Endocrinol Metab. 2017;102:1001–8.
37. Kaplowitz P. Pubertal development in girls: secular trends. Curr Opin Obstet Gynecol. 2006;18:487–91.
38. Herman-Giddens ME, Kaplowitz PB, Wasserman R. Navigating the recent articles on girls’ puberty in pediatrics: what do we know and where do we go from here? Pediatrics. 2004;113:91–7.